ReproCELL, a stem cell company, has announced that the company on August 3 will commence the sales of 'ReproNeuro MQ Medium', a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells.

The 'ReproNeuro' series which the company has sold so far enables the creation of nerve cells from human iPS cells, and has been widely used by pharmaceutical companies during the drug development process for the evaluation of nerve cell toxicity. It has been highly rated for its ability to reduce the number of experiments previously required to be performed on animal subjects. ReproCELL have continued research and development in order to bring these nerve cells closer to the ideal of being like those within a living human body.

With this new 'ReproNeuro MQ Medium', the company has developed a specialist culture fluid for making nerve cells, and succeeded in increasing the electrical activity of nerve cells created from iPS cells. The company expects this to distinguish its superior nerve cell development, to lead to both an improvement in the reliability of and expansion in the utility of toxicity evaluations in the drug development process, and to contribute to a major reduction in the cost of the drug development process.